MEDICATION TREATMENT FOR ADHD IN ADULTS

Abstract

This study conducted a narrative review of the literature with the aim of deepening understanding of the pharmacological interventions available for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults, with a special focus on drugs available in Brazil. The research analyzed the main therapeutic options, including stimulants such as methylphenidate and amphetamines, non-stimulants such as atomoxetine, as well as antidepressants and other drug alternatives. The results indicate that stimulants are the first-line medications due to their rapid action and effectiveness in reducing the core symptoms of ADHD, while non-stimulants are useful in cases of contraindication, intolerance, or psychiatric comorbidities. Antidepressants and other drugs, although considered third-line, may be indicated in specific situations, requiring close monitoring. The analysis also highlights the potential risks associated with prolonged use of medications, including adverse cardiovascular and psychiatric effects, which reinforces the importance of individualized clinical assessment in therapeutic choice. It is concluded that effective management of ADHD in adults requires a personalized approach that considers the patient's clinical profile and history, with attention to safety, tolerability, and associated comorbidities. The combination of pharmacological and psychotherapeutic interventions emerges as a promising strategy to promote greater treatment adherence, functionality, and long-term quality of life.